In a patient who had a ketotic hypoglycemia episode with marked metabolic acidosis (low serum bicarbonate), is mitochondrial acetoacetyl‑CoA thiolase (T2) deficiency or succinyl‑CoA:3‑oxoacid CoA‑transferase (SCOT) deficiency more likely?

SCOT Deficiency is More Likely

In a patient with ketotic hypoglycemia and marked metabolic acidosis (serum CO2 of 17 mEq/L), SCOT deficiency is more likely than T2 deficiency. The presence of severe metabolic acidosis during a ketotic hypoglycemia episode is a distinguishing feature that points toward SCOT deficiency.

Key Distinguishing Features

Why SCOT Deficiency is More Likely

Permanent or severe ketosis is pathognomonic for SCOT deficiency 1, 2. The marked metabolic acidosis (CO2 of 17 mEq/L) during this episode suggests profound ketoacidosis, which is characteristic of SCOT deficiency. SCOT-deficient patients typically present with:

• Severe ketoacidotic crises with blood pH often <7.1 and bicarbonate <6 mEq/L 3, 4
• Persistent ketonuria between episodes (though patients with "mild" mutations may have non-ketotic periods) 1, 2
• Blood total ketone bodies that can exceed 29 mmol/L during crises 3
• Neonatal presentation is common (approximately 25% present in the neonatal period, 70% in the first year) 4

T2 Deficiency Characteristics

T2 deficiency generally presents with:

• Less severe acidosis compared to SCOT deficiency 5
• Median age at first episode of 15 months (range 3 days to 48 months) 5
• Favorable outcome with 23 of 26 patients developing normally 5
• Episodes typically cease by age 10 years 5
• No permanent ketosis has been reported 1, 2

Clinical Algorithm for Differentiation

Immediate Assessment

1. Evaluate ketone body pattern during crisis:

   • Measure blood total ketone bodies and beta-hydroxybutyrate
   • Check urinary organic acids for 2-methyl-3-hydroxybutyrate and tiglylglycine
   • In SCOT deficiency: expect extremely elevated ketones (>20-30 mmol/L possible)
   • In T2 deficiency: ketones elevated but typically less severe

2. Assess between episodes:

   • Persistent ketonuria (1+ to 3+ on ketostix) between crises strongly suggests SCOT deficiency 3
   • Normal ketone levels between episodes favor T2 deficiency

Diagnostic Confirmation

• Urinary organic acid analysis:

  • SCOT deficiency: marked elevation of acetoacetate and 3-beta-hydroxybutyrate 6
  • T2 deficiency: 2-methyl-3-hydroxybutyrate with or without tiglylglycine 5, 7

• Blood acylcarnitine profile:

  • T2 deficiency may show elevated C5:1, C5OH, and C4OH (C4OH is particularly significant) 7
  • SCOT deficiency does not show these specific acylcarnitine elevations

• Genetic testing:

  • SCOT: OXCT1 gene mutations 4
  • T2: ACAT1 gene mutations 5, 7

Important Caveats

Genotype-Phenotype Considerations

• "Mild" SCOT mutations may not show permanent ketosis 1, 2, 3, making diagnosis more challenging
• T2-deficient patients with "mild" mutations may have normal acylcarnitine profiles even during crises 1
• Both conditions show variable clinical severity that doesn't always correlate with genotype 5

Hypoglycemia Patterns

• Hypoglycemia can occur in SCOT deficiency, particularly in neonatal-onset cases 8, 3, though it's not the defining feature
• The combination of hypoglycemia with severe ketoacidosis (CO2 of 17) is more consistent with SCOT deficiency

Mortality Risk

• SCOT deficiency has approximately 5% mortality during acute crises 4
• T2 deficiency has more favorable outcomes with only 1 of 26 patients dying in one series 5

Management Implications

Regardless of which deficiency is confirmed, immediate management is similar:

• Intravenous glucose infusion (38 μmol/kg/min or 6.8 mg/kg/min) 8
• Sodium bicarbonate for severe acidosis
• Avoid fasting
• Long-term: modest protein restriction and frequent feeding 5, 2

The severity of acidosis in your patient (CO2 of 17) warrants aggressive treatment and strongly suggests SCOT deficiency as the more likely diagnosis, pending confirmatory enzyme studies or genetic testing 1, 2, 4.